The factors determining the growth and survival of cells in B chronic lymphocytic leukemia (CLL) have remained poorly understood. We investigated the effects of optimal mitogen combinations (OMCs) on the expression of 26 surface membrane antigens among 33 CLL patients. The seven OMCs used were selected after pre-testing 14 combinations of (1) S. aureus Cowan I (SAC), (2) interleukin-2 (IL-2), (3) tumor necrosis factor alpha (TNF-␣) and (4) 12-O-tetradecanoylphorbol 13-acetate (TPA; also known as phorbol 12-myristate 13-acetate or PMA). In flow cytometry we revealed that OMCs induced statistically highly significant upregulation of the expression of CD5, CD11c, CD19, CD22, CD23, CD25, CD38, CD40, CD45, CD45RO, CD95, CD126, CD130 and FMC7, and downregulation of CD20 and CD124 expression. Interestingly, the expression of CD27, CD45RA, CD79b, CD80, CD122 and that of the immunoglobulin gene superfamily members CD21, Ig-, Ig-, Ig-␦ and Ig-were not significantly affected under similar conditions. The expression of several antigens was co-regulated, suggesting common regulatory pathways. These antigens include CD11c/CD5, CD11c/CD22, CD11c/CD126, CD11c/FMC7 as well as CD27/CD45, CD27/CD45RA and CD27/CD79b. Upregulation of surface antigen expression, induced by OMCs, should be applicable in antibody therapy in vitro and in vivo, and in negative stem cell selection for autotransplantation. Furthermore, the current strategy to enhance cell surface antigen expression may be a versatile tool to raise humoral and cell-mediated host defense against CLL cells. Upregulation of proteins mediating positive growth signals (eg CD25, CD40) and negative signals or apoptosis (eg CD95) may be used to sensitize cells to chemotherapy and programmed cell death.
Introduction
Chronic lymphocytic leukemia (CLL) is a clonal B cell neoplasm of small, resting, long-lived B cells. Despite recent advances in understanding of the genetics, 1 biology, 2 treatment, 3 and clinical behavior 4 of CLL, there is still no established cure for the disease, and its progression and outcome are highly unpredictable. New strategies are required.
CLL cells co-express low levels of surface membrane immunoglobulins (SmIgs) and the CD5 molecule. The dominant immunophenotype is easily detectable by flow cytometry: weak SmIg, positive CD5, positive CD23, negative FMC7, weak/negative CD22, and negative CD79b. 5, 6 Many membrane molecules are known to influence B-CLL tumor cells through their effects on the mechanisms regulating cell proliferation and apoptosis. These include, for instance, IL-2 receptor components (CD25, CD122 and CD132), 7 IL-4 receptor (CD124), 8, 9 IL-6 receptor (CD126), 9 as well as tumor necrosis factor receptor superfamily members, such as CD30, 10 CD40 11-13 and CD95. [14] [15] [16] In addition to the data accumulated concerning their biochemical actions and cellular functions, some interesting clinical aspects of several membrane antigens are emerging. The marked heterogeneity in the clinical course of patients with apparently similar features can be explained by variable expression of regulatory molecules. This, on the other hand, should provide novel ways to intervene in the clinical course of CLL progression. All these aspects point to the importance of membrane signals mediated by a large number of molecules. The aim of the present work was to investigate whether the expression of membrane antigens can be altered. The challenging molecules were selected according to their capacity to induce maximal proliferation in vitro. For this purpose, the most effective mitogen combination for each patient was chosen from a panel of 14 combinations of four B-CLL cell mitogens, as previously described. [17] [18] [19] 
Materials and methods

Patients and samples
Clinical specimens were obtained after informed consent from 33 CLL patients referred to the CLL out-patient clinic at Tampere University Hospital. Diagnosis and staging were based on standard clinical, morphological and immunophenotyping criteria. All patients had a CD19
+ immunophenotype, and mature CLL, CLL/mix or CLL/PL morphology. Most patients had chromosomal aberrations, but none indicating chronic lymphoid leukemias other than typical CLL. 20 The clinical hematological data of the 33 CLL patients are illustrated in Table 1 .
Peripheral blood mononuclear cells were isolated from heparinized (Noparin; Novo Nordik, Dagsvaerd, Denmark) blood samples by centrifugation over a Lymphoprep layer (Nycomed, Oslo, Norway) at a density of 1.077 g/ml. The cells were washed twice with phosphate-buffered saline (PBS, pH 7.4) and once with medium consisting of RPMI 1640 (20 mM Hepes; ICN Biochemicals, Costa Mesa, CA, USA), 10% heat-inactivated fetal calf serum (Gibco BRL, Paisley, UK), 2 mM L-glutamine (Gibco BRL) and antibiotics (Gibco BRL, penicillin, 50 U/ml, streptomycin, 50 g/ml). Cell counting was performed by using Technicon H1, H2 or H3 analyzers (Bayer Diagnostica, Tarrytown, NY, USA). Density gradient centrifugation yields -without other purification steps -have been good (range 29-92%, mean 61.7%, s.d. 16 .2%, n = 36), as previously described. This information is necessary for interpretation of the results. 21 The proportion of monocytes plus polyclonal T and B lymphocytes was 1-13%, indicating that 87-99% of the isolated cells represented the leukemic population. 4 = SAC (0.005%) + IL-2 (10 U/ml), 6 = TPA10 (10 ng/ml) + IL-2 (10 U/ml), 8 = TPA1 (1 ng/ml) + IL-2 (10 U/ml), 10 = TNF-␣ (10 ng/ml) + IL-2 (10 U/ml), 11 = TNF-␣ (10 ng/ml) + TPA1 (1 ng/ml), 12 = TNF-␣ (10 ng/ml) + TPA1 (1 ng/ml) + IL-2 (10 U/ml), 14 = TNF-␣ (10 ng/ml) + TPA10 (10 ng/ml) + IL-2 (10 U/ml). IL-2, interleukin-2; SAC, Staphylococcus aureus Cowan 1; TPA, 12-O-tetradecanoylphorbol 13-acetate; TNF-␣, human recombinant tumor necrosis factor alpha; S (slow), blood lymphocytes increased less than 20% within a year; F (fast, lymphocyte doubling time 1 year or less; I (intermediate) between S and F; T (therapy), chemotherapy given, natural disease progression non-evaluable; L, Leukeran (chlorambucil); P, predniso(lo)ne; CH(O)P, cyclophosphamide-hydroxydaunorubicin (doxomycin)-oncovine (vincristine)-prednisolone.
Proliferation and activation of CLL cells in suspension cultures
Mononuclear cells were incubated in 200 l aliquots (2 × 10 6 cells/ml) in RPMI-1640 medium (vide supra) at +37°C in a humidified atmosphere containing 5% CO 2 . Mitogens were used according to Table 1 : these were IL-2 (BoehringerMannheim, Mannheim, Germany); TPA (Sigma Chemical, St Louis, MO, USA); SAC (Pansorbin Cells; Calbiochem-Novabiochem, La Jolla, CA, USA) and TNF-␣ (Immunex, Los Angeles, CA, USA). Proliferation activity and total protein synthesis of the cells were measured as the rate of incorporation of (methyl- 
Immunophenotyping
Immunophenotyping was performed with cryopreserved cells by using flow cytometry (FACSCalibur, Becton Dickinson Immunocytometry Systems, Mountain View, CA, USA) and commercial mouse monoclonal antibodies with respective immunoglobulin isotype controls ( Table 2 ). The expression of antigens was determined after 4 days in vitro stimulation with an OMC (time point D4) and compared with that of cells analyzed immediately after thawing (D0). Staining was performed according to the suppliers' instructions. For cell surface immunoglobulin staining, the cells were first incubated in PBS (pH 7.4) at 37°C for 30 min to remove heterophilic antibodies. The buffers used in all the steps did not contain serum.
The forward scatter channel was checked prior to every analysis using unlabeled calibration particles (SPHERO Calibration Particles, blank 6.5-8 m; Pharmingen, San Diego, CA, USA). Instrument linearity was checked using commercial standard reagents (Immuno-Brite Standards Kit, Coulter, Hialeah, FL, USA) prior to the study. Fluorescence compensations were set prior to every analysis using calibration beads (caliBRITE; Becton Dickinson) and FACSComp software (Becton Dickinson). Instrument calibration was additionally checked using Immunobrite level II standard beads (Coulter). On the basis of the data obtained, the interassay variability in this study was 6.5% for the FL1 channel and 7.6% for the FL2 channel.
The percentages of cells were calculated on the basis of data obtained from two-color immunofluorescence dot blots (results not shown). Analyses were carried out using CellQU-EST Software (Becton Dickinson). Quadrant markers were set relative to negative immunoglobulin isotype controls in a such way that 99% (99.05 ± 0.04) of the cells labeled with control antibodies were located in the left lower quadrant. When estimating the reactivity of known T cell antigens on the surface of malignant B cells, the proportion of CD2 cells was taken into account. The intensity of antigen expression in the cell There were some drop-outs from the analyses, as indicated by the numbers in Figure 1 . Firstly, SAC particles adhered very tightly to CLL cells in 4-day cultures. Owing to the strong binding of labeled antibodies to the SAC particles, flow cytometric determination of membrane antigens in SAC-stimulated cultures was impossible. Secondly, in some cases the mitogens induced very strong aggregation of cells, making reasonable surface membrane antigen determinations impossible.
Statistical treatment
Statistical analyses were performed using a statistical package: STATISTICA for Windows (ver. Win 5.1D, 1996, StatSoft, Tulsa, OK, USA).
Results
Cell surface antigen expression changes induced by optimal mitogen combinations
A statistically significant difference (P Ͻ 0.001, Wilcoxon matched pairs test; GMF on D4 minus GMF on D0) was noted with 16 of the 26 surface antigens when expression of unstimulated cells was compared with that of cells stimulated for 4 days ex vivo. In most cases the OMC induced enhancement of expression (Figure 1 ). Only CD20 and CD124 were repressed. Individual changes were also noted in regard to ten other antigens, but no common up-or downregulation trends were demonstrable (Table 3) .
Association of membrane antigen expression changes with proliferation and activation
Proliferation and activation results are not shown in detail, but similar results have been published elsewhere. 17, 19 Proliferation per se was not significantly associated with antigen expression changes (Table 4) . Surprisingly, a negative correlation was observed concerning CD5 and CD11c, showing that suppressed proliferation was associated with strong upregulation of these antigens. The protein synthesis-based activation index, assessed by leucine incorporation, correlated with the expression changes of several antigens (Table 4) . Interestingly, the correlation was negative in some cases. (See also discussion concerning problems with multiple correlations, below.)
Correlations between the expression changes of different antigens
We also analyzed whether possible co-regulation of changes in the expression of different antigens took place. To this end,
Figure 1
Effect of optimal mitogen combinations in 4-day cultures on the surface membrane expression (geometric mean fluorescence) of 16 antigens showing a statistically significant change (P Ͻ 0.001, as analyzed by using Wilcoxon matched pairs test). The numbers of eligible CLL patients are given above each chart. Point, median; whiskers, min and max; rectangles, 25-75%. Note that CD124 and CD20 were downregulated by the OMCs. the rank order correlations among the 26 antigens were analyzed. Owing to the great number of comparisons, we have chosen to illustrate only the most significant correlations (Figure 2) . Interestingly, CD11c and CD27 were co-regulated with four and three other antigens, respectively. A negative, albeit non-linear correlation, was observed with the changes of CD23 and CD95 expression.
Kinetics of induction of surface membrane antigens
The analysis of the kinetics of some example antigens demonstrated that additional induction may take place after day 4 ( Figure 3 ).
Discussion
In this study we examined the effects of four known CLL cell growth promoters (SAC, IL-2, TPA, TNF-␣) on the interrelationships, in vitro, between the rate of CLL cell proliferation, total protein synthesis and the expression of 26 cell surface membrane antigens. The growth promoting mechanisms of these modulators in normal B cells are gradually emerging and similar signaling pathways are also operative in B-CLL, although not necessarily in an identical manner as in normal B cells (for a review, see Meinhardt et al 2 ) . In this study we selected seven mitogen combinations from a set of 14. This set was previously formed on the basis of four known B-CLL cell mitogens tested in this laboratory. [17] [18] [19] Several novel features concerning surface membrane antigen expression emerged from the present analyses. The current data clearly demonstrated that many different types of membrane antigen are inducible or repressible under certain conditions. Information about cell surface membrane antigen regulation in CLL is very limited. In a recent investigation it was reported that several CLL cell antigens, including CD58, CD80, CD86, and MHC class I molecules, can be upregulated by CpG-oligonucleotides. 22 Another immunostimulant, the guanosine analog loxoribine, effectively upregulated CLL surface anti- CLL cells were incubated in vitro for 4 days in the presence of an optimal mitogen combination, whereafter surface antigen expression was determined by using flow cytometry and fluorescent antibodies as described in Materials and methods. The 'Day 0' cells were assessed without stimulation.
Table 4
Relationship of proliferation (thymidine incorporation) and total activation (leucine incorporation) with the OMC-induced antigen expression change as assessed by using Spearman's rank order correlation. Only statistically significant results (P Ͻ 0.05) are illustrated gens such as CD22, CD23, CD25, CD38 and CD54, while CD5, CD11c, CD20, HLA-DR, and mIg-showed little or no change. 23 Furthermore, it has been shown previously that the CD40-ligand (CD40L) CD154 increases the expression of CD40, CD54, CD69, CD70, CD80 and CD95, whereas the protein kinase C modulator bryostatin-1 increased expression of CD40, CD54, CD69 and CD95. 24 To our knowledge, our OMC strategy provides, for the first time, tools to upregulate CD5, CD11c, CD19, CD22, CD23, CD25, CD38,CD40, CD45, CD45RO, CD95, CD126, CD130 and FMC7, and downregulate CD20 and CD124 in CLL cells.
CD5 is a signal transducing molecule from the scavenger receptor superfamily (see http://www.ncbi.nlm.nih.gov/ PROV/guide for upgraded information about this and other Leukemia proteins discussed here). The importance of CD5 in CLL immunophenotyping is established. However, as recently reviewed, the role of CD5 as an independent lineage marker for normal polyclonal human CD19
+ has remained unresolved. 25 Another possibility exists that CD5 is an activation marker. The present investigation demonstrated that this is the case in CLL cells; a positive correlation was observed between OMC-induced activation (protein synthesis) and enhancement of the expression of CD5. A similar correlation has been previously noted between the release of a known activation marker, ie beta-2-microglobulin, and protein synthesis in OMC-stimulated CLL cells. 19 The negative correlation of CD5 with proliferation, as demonstrated here, suggests that CD5 intensity cannot be used as a proliferation marker for CLL cells.
We also demonstrated a variable but in some cases remarkable enhancement of CD11c expression in OMC-treated CLL cells. CD11c is an integrin alpha X chain of the CD11c/CD18 adhesion molecule, which mediates leukocyte spread on to protein-coated surfaces. Low levels of expression have been recorded in CLL cells. [26] [27] [28] Higher intensities have been associated with early-stage disease, 27 while cells with 11q deletion carry significantly lower amounts of CD11c. 28 It remains to be resolved why low expression of CD11c, a molecule mediating leukocyte spread, is paradoxically associated with 11q deletion, a marker of poor prognosis of CLL. 1 The current approach provides a means to upregulate CD11c expression and possibly to affect the biological behavior of CLL cells. We also demonstrated that the expression of CD5, CD22 (an adhesion and signaling molecule), CD126 (IL-6 receptor) and FMC7 (currently unknown function) are co-modulated, with CD11c, by OMCs. There is a possibility that this simply reflects a common 'non-specific' activation, since the enhancement of expression of all these antigens was associated with the enhancement of total protein synthesis. Similar co-regulation was observed as regards CD27 (tumor necrosis factor receptor family), with CD45, CD45RA and CD79b. Although CD27 is known to mediate a co-stimulatory signal of B cell activation, more precise interpretation of its role in OMC-stimulated B-CLL cells requires that its basic cellular functions become better characterized.
CD19 is a B lymphocyte development, activation and differentiation regulator. Considerable enhancement of this B cell co-receptor member by OMCs is in contrast to the regulation of its complementation partner CD21 and other B cell receptor-associated molecules or SmIg types examined here. The overall activation of CLL cells does not explain this exception, since the protein synthesis rate was inversely correlated to CD19 expression enhancement. The significance of CD19 in CLL as well as its increased expression in OMC-treated cells, as shown here, remains to be determined. CD20 and CD124 were the only OMC-downregulated antigens in this investigation. The precise functions of CD20 are currently unknown. The structure of CD20, however, indicates that it may be involved in the regulation of B cell activation and proliferation. Hence, modulation of these putative functions by OMCs is possible. It is conceivable that similar downregulation of CD20 expression may also take place in vivo and should be taken into account in anti-CD20 antibody therapy and in anti-CD20-based in vitro purging and negative selection of stem cell preparations processed for autotransplantation.
CD23 belongs to the sialoadhesins of immunoglobulin supergene family products. It functions as an IgE synthesis regulator and triggers cytokine release by human monocytes;
Figure 2
Spearman rank order correlations between the expression changes of different surface membrane antigens (P р 0.0004). A negative correlation between the changes in CD23 vs CD95 is illustrated in the last panel. Correlation coefficient R, significance (P) and the number of eligible patients are given above each panel.
Figure 3
Kinetics of induction on days 0-6 of four example antigens of two patients.
TNF␣, IL-1, IL-2 and GM-CSF. CD23 ligands include CD21 and CD11c, the latter being remarkably upregulated by OMCs. This may indicate collaboration of CD11c and CD23 in OMC-treated B-CLL cells. CD23 is unstable on CLL cells; in vivo, it is rapidly cleaved from the surface into a stable form, sCD23 (reviewed by Molica 29 ). Serum sCD23 is an established risk factor in CLL. Remarkable enhancement of CD23 expression was induced by OMCs in vitro. It is conceivable that similar cytokine modulation may mark progressive disease in vivo.
CD38 has multiple functions, such as NAD glycohydrolase, ADP-ribosyl cyclase, cyclic ADP ribose hydrolase and baseexchange activities. Particular interest in this molecule in CLL is based on its possible value as a marker of poor prognosis 30, 31 and its association with the naive or unmutated maturation stage of the disease. 30 In some cases, remarkable enhancement of CD38 expression was induced by an OMC. The most effective combinations in this regard were Nos 8, 10 and 11 (Table 1) , ie TPA + IL-2, TNF␣ + IL-2 and TNF␣ + TPA. This demonstrates that physiological cytokines and protein kinase C modulators may be involved in the regulation of CD38 expression. IL-2 and TNF␣ have thoroughly been investigated in B-CLL and their role in disease progression is evident, as recently reviewed. 32 The upregulation of CD38 by TNF␣, IL-2, or both, as well as by agents modulating protein kinase C activity, may explain the high expression of CD38 in progressive forms of CLL.
CD40 is a member of the tumor necrosis factor receptor superfamily gene products, which have functions in B lymphocyte growth, differentiation and isotype-switching as well as in rescue signaling from apoptosis in germinal center cells. Native B-CLL cells are unable to function effectively as antigen-presenting cells, and they fail to induce a relevant T cell immune response. Therefore, the CD40 pathway in B-CLL cells has been actively investigated. Expression of both CD40 and CD154 (CD40L) may have an autocrine or paracrine function in cell growth (reviewed by Orsini and Foa 32 ). The most effective upregulators of CD40 were OMC combinations 6, 8 and 10 (Table 1) , containing TPA + IL-2 and TNF␣ + IL-2. It has been demonstrated that the serum of patients with B-CLL contains increased levels of CD40L 33 and that the CD40/CD40L system may be effective in inhibiting the apoptotic response to fludarabine. 34 As discussed above, TNF␣ and IL-2 are thought be involved in CLL progression 32 and the present results imply that upregulation of their signaling cascades may be a mediator of proliferation and resistance to apoptosis. It is also noteworthy that the expression of IL-2 receptor subunits, as exemplified by the alpha subunit (CD25) is enhanced by OMCs. This kind of receptor amplification may further potentiate the anti-apoptotic (via CD40) and growth promoting (via CD38?) effects of IL-2.
Remarkable upregulation of CD95 was induced by OMCs in most of the patients. CD95 (APO-1 or Fas ligand) is a transmembrane glycoprotein that belongs to the TNF receptor superfamily. It is thought to be one of the principal mediators of apoptosis-inducing signals. In addition to CD40L and bryostatin-1 (see above), upregulation of CD95 by IFN␣, IFN␥ and SAC has been observed in other laboratories, as recently reviewed. 32 B-CLL cells may be resistant to CD95-mediated apoptosis, 32 but this certainly is a sum effect of many regulators of apoptotic pathways. Hence, it remains to be investigated if the considerable upregulation of CD95 by OMCs can be used to kill B-CLL cells.
A monoclonal antibody against FMC7 detects an antigen that is present in types of chronic lymphoid leukemia other than typical B-CLL (eg B-PLL, HCL, leukemic non-Hodgkin's lymphoma). 5, 6 It has recently been proposed that FMC7 antigen expression on normal and malignant B cells can be predicted by the expression of CD20. 35 This may be explained by the recent finding that FMC7 antibody detects a conformational epitope on the CD20 molecule. 36 The current data demonstrated a good correlation between CD22 and FMC7 expression changes (R = 0.59, P = 0.0007, Spearman's rank order correlation) and the epitope bound by the FMC7 antibody may be closer to other antigens co-regulated with CD11c, ie CD5 and CD126, in addition to CD22, than to CD20. No correlation was seen between FMC7 and CD20 (R = −0.06, P = 0.76). This indicates very different regulation of epitopes detected by FMC7 and CD20 antibodies under the OMC-stimulation used in this work.
Although B prolymphocytic leukemia (B-PLL) can be distinguished as a separate independent clinical and immunological entity, 37 many features are similar to those of B-CLL, in particular, atypical and transformed cases of B-CLL. It is interesting to note that several B-CLL antigens can be upregulated, as shown here, so that the immunophenotype starts to resemble that of B-PLL. These antigens include FMC7, CD22, CD79b, CD25, CD11c and CD38, 37 indicating that OMC-like factors may be particularly operative in vivo in B-PLL. This is in accordance with the fast clinical progression of that disease.
In this study we used multiple comparison procedures, which have an internal tendency to reveal non-existing correlations. On the other hand, there are very few possibilities to accurately determine the P values in this kind of situation. One robust and very conservative approach is based on Bonferroni-type inequality, generally used with variance analysis, in which each P value inside a comparison family is multiplied by the number of comparisons. Taking this into consideration, only the results with the smallest P values are presented.
To conclude, our most prominent findings are significant up-or downregulation of a number of 'new' B-CLL surface antigens by using individually selected optimal mitogen combinations. Furthermore, novel co-regulation of several antigens was observed. These molecules are important in cell signaling, growth promotion and apoptosis induction or prevention, for example. Our results introduce new aspects to strategies in B-CLL research: (1) understanding and intervention in proliferation and apoptosis by means of regulation via immunomodulators, (2) enhancing the expression of interesting candidate antigens for in vitro antibody purging and in vivo antibody therapy as well as for negative selection of stem cells for autotransplantation. This should ultimately lead to a better understanding of the clinical behavior of CLL as well as to the development of novel treatment strategies. Both are urgently needed in CLL.
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